Wall Street is positive on C4 Therapeutics Inc (CCCC). On average, analysts give the stock a Buy rating. The average price target is $15.272, which means analysts expect the stock to climb by 787.91% over the next twelve months.
That average ranking earns the stock an Analyst Rating of 33, which is better than 33% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating CCCC a Buy today. Find out what this means to you and get the rest of the rankings on CCCC!
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With C4 Therapeutics Inc Stock Today?
C4 Therapeutics Inc (CCCC) stock is down -2.27% while the S&P 500 has risen 1.09% as of 1:19 PM on Friday, Nov 10. CCCC is down -$0.04 from the previous closing price of $1.76 on volume of 121,647 shares. Over the past year the S&P 500 has gained 11.08% while CCCC is down -80.43%. CCCC lost -$2.85 per share the over the last 12 months.
Click Here to get the full Stock Report for C4 Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
